Dry January doesn't have to mean sober January — at least for the 21 percent of participants turning to cannabis or CBD to make it through the month.
According to a survey by Civic Science, 67 percent of Dry January participants, or those choosing to abstain from alcohol consumption for the month of January, reported they are replacing alcohol with something — whether that be mocktails and alcohol-free beers or sodas and seltzers.
The largest share, 21 percent, said they would enjoy cannabis or non-psychoactive CBD in place of alcohol. The preference for substitutes wasn't uniform across all respondents. Cannabis was the most popular substitute among the youngest respondents with 34 percent of 21- to 24-year-olds preferring it. Among the 55 and older crowd, by contrast, just 9 percent reported they'd enjoy cannabis or CBD instead of alcohol, and 54 percent reported they'd stay the course without any support.
Dry January's Growing Popularity
Interest in Dry January has climbed over the recent years. At the close of 2022, about 41 percent of respondents in a separate survey by Civic Science reported they were "somewhat to very likely" to participate in Dry January come 2023. That's in-line with pre-pandemic data for the start of 2020, but slightly behind 2022 responses, which rebounded after a lag in interest during the 2021 pandemic year.
As with the preference for cannabis, interest in Dry January tends to vary by age — and younger generations are leading the charge. For the year of 2023, more than half of the youngest respondents, aged 21 to 24 years old, said they were "somewhat to very likely" to participate versus just 41 percent of those 55 and older.
Studies suggest social media is contributing to a growing reluctance to drink with younger generations fearful of consequences if their drunk escapades are documented on the internet. According to 2019 research from Google, 49 percent of Generation Z reports their image online is "always at the back of their mind when they go out socializing and drinking." Some 76 percent reported it is important to have control of "all aspects of their life at all times," according to the research.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
